Vermillion Presents Protein Biomarker Study Supporting OVA2 Ovarian Cancer Test
March 11, 2011
Vermillion Presents Protein Biomarker Study Supporting OVA2 Ovarian Cancer Test
According to the company, the study, which was presented at the 42nd Annual Meeting on Women's Cancer of the Society of Gynecological Oncologists, examined more than 20 candidate biomarkers, identifying three potentially useful analytes.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
October 19, 2012 / ProteoMonitor - Vermillion Performs 3,920 OVA1 Tests in Q2, But Revenues Fall 9 Percent on Drop in Licensing Income
August 5, 2011 / ProteoMonitor - Vermillion Posts $431K in Q1 Revenue, Anticipates Two Peer-Reviewed Articles on OVA1
May 13, 2011 / ProteoMonitor - Vermillion Signs Better Revenue-Splitting Deal with Quest for OVA1, Lowers Full-Year Sales Guidance
November 12, 2010 / ProteoMonitor - Vermillion Granted US Patent Supporting PAD Biomarker
September 17, 2010 / ProteoMonitor